node_id	target	category	weight	source
AO1	cancer	AO	0.21122112211221122	RE28
AO1	cancer	AO	0.1901639344262295	RE52
AO2	decreased fertility	AO	0.2174863387978142	RE52
AO1	cancer	AO	0.6315331010452961	RE77
AO1	cancer	AO	0.45677233429394815	RE124
AO1	cancer	AO	0.6737089201877934	RE125
AO1	cancer	AO	0.3277404921700224	RE150
AO1	cancer	AO	0.14073426573426573	RE178
KE1030	increased 	KE	1.0	RE7
KE768	increase cytotoxicity	KE	4.5	RE10
KE770	increase cytotoxicity (club cells)	KE	-2.25	RE10
KE776	increase cytotoxicity (corneal cells)	KE	-2.25	RE10
KE780	increase cytotoxicity (epithelial cells)	KE	-2.25	RE10
KE794	increase cytotoxicity (urothelial cells)	KE	-2.25	RE10
KE1030	increased 	KE	1.0	RE10
KE1030	increased 	KE	1.0	RE12
KE169	disruption membrane integrity	KE	1.3333333333333333	RE17
KE1030	increased 	KE	1.0	RE20
KE808	decreased testosterone	KE	1.5	RE27
KE494	glucocorticoid receptor agonist activation	KE	-2.0	RE28
KE742	decreased androgen receptor activity	KE	-2.25	RE28
KE785	activation androgen receptor	KE	3.0	RE28
KE1193	breast cancer	KE	1.0	RE28
KE1030	increased 	KE	1.0	RE36
KE201	binding antagonist nmda receptors	KE	-1.25	RE41
KE1030	increased 	KE	1.0	RE43
KE312	allergic contact dermatitis challenge	KE	-0.75	RE46
KE1030	increased 	KE	1.0	RE44
KE1262	apoptosis	KE	1.0	RE44
KE1030	increased 	KE	1.0	RE45
KE277	decrease thyroid hormone synthesis	KE	2.5	RE48
KE286	decreased transcription genes ar	KE	-3.25	RE48
KE1021	increased t4 t3 catabolism	KE	-1.0	RE48
KE1030	increased 	KE	1.0	RE48
KE1030	increased 	KE	1.0	RE51
KE1157	activation hepatic nuclear receptor(s)	KE	-2.0	RE51
KE1396	increased glucocorticoid receptor activity	KE	-3.75	RE51
KE1030	increased 	KE	1.0	RE53
KE330	decrease fertility	KE	1.0	RE52
KE885	increase cancer	KE	3.0	RE52
KE1030	increased 	KE	1.0	RE52
KE1193	breast cancer	KE	2.0	RE52
KE1447	obesity	KE	1.0	RE52
KE312	allergic contact dermatitis challenge	KE	-0.75	RE56
KE312	allergic contact dermatitis challenge	KE	-0.75	RE58
KE1030	increased 	KE	1.0	RE60
KE1030	increased 	KE	1.0	RE66
KE312	allergic contact dermatitis challenge	KE	-0.75	RE71
KE1030	increased 	KE	1.0	RE70
KE446	reduction testosterone level	KE	2.3333333333333335	RE73
KE1030	increased 	KE	1.0	RE73
KE130	depletion gsh	KE	1.0	RE76
KE249	production reactive oxygen species	KE	-0.75	RE76
KE1030	increased 	KE	1.0	RE76
KE1115	increased reactive oxygen species	KE	-0.75	RE76
KE1278	ros formation	KE	1.0	RE76
KE1445	increase lipid peroxidation	KE	1.0	RE76
KE1447	obesity	KE	1.0	RE77
KE312	allergic contact dermatitis challenge	KE	-0.75	RE80
KE312	allergic contact dermatitis challenge	KE	-0.75	RE82
KE312	allergic contact dermatitis challenge	KE	-0.75	RE81
KE1030	increased 	KE	1.0	RE85
KE1030	increased 	KE	1.0	RE86
KE312	allergic contact dermatitis challenge	KE	-0.75	RE90
KE1030	increased 	KE	1.0	RE95
KE1030	increased 	KE	1.0	RE97
KE1447	obesity	KE	1.0	RE97
KE1030	increased 	KE	1.0	RE102
KE1030	increased 	KE	1.0	RE101
KE294	unknown	KE	1.0	RE104
KE1030	increased 	KE	1.0	RE104
KE1113	unknown 	KE	1.0	RE104
KE1030	increased 	KE	1.0	RE113
KE1030	increased 	KE	1.0	RE116
KE1030	increased 	KE	1.0	RE123
KE1030	increased 	KE	1.0	RE121
KE416	increase proliferation leydig cell 	KE	-1.0	RE124
KE870	increase cell proliferation	KE	1.3333333333333333	RE124
KE923	increase proliferation goblet cells	KE	-1.0	RE124
KE1030	increased 	KE	1.0	RE124
KE1033	increased proliferation mesenchymal cells	KE	-1.0	RE124
KE1089	increased cell proliferation (mesothelium)	KE	-1.0	RE124
KE1182	increase cell proliferation (epithelial cells)	KE	-1.0	RE124
KE1189	increased proliferation (endothelial cells) 	KE	-1.0	RE124
KE1193	breast cancer	KE	1.0	RE124
KE364	impaired development of reproductive organs	KE	-0.75	RE125
KE1205	activation juvenile hormone receptor	KE	-1.5	RE125
KE1030	increased 	KE	1.0	RE127
KE1030	increased 	KE	1.0	RE126
KE312	allergic contact dermatitis challenge	KE	-0.75	RE129
KE210	oxidative stress	KE	1.0	RE137
KE1249	oxidative stress 	KE	1.0	RE137
KE1278	ros formation	KE	2.0	RE137
KE1392	oxidative stress 	KE	1.0	RE137
KE210	oxidative stress	KE	1.0	RE141
KE1249	oxidative stress 	KE	1.0	RE141
KE1392	oxidative stress 	KE	1.0	RE141
KE416	increase proliferation leydig cell 	KE	-1.0	RE150
KE870	increase cell proliferation	KE	1.3333333333333333	RE150
KE923	increase proliferation goblet cells	KE	-1.0	RE150
KE1030	increased 	KE	1.0	RE150
KE1033	increased proliferation mesenchymal cells	KE	-1.0	RE150
KE1089	increased cell proliferation (mesothelium)	KE	-1.0	RE150
KE1182	increase cell proliferation (epithelial cells)	KE	-1.0	RE150
KE1189	increased proliferation (endothelial cells) 	KE	-1.0	RE150
KE1193	breast cancer	KE	1.0	RE150
KE1030	increased 	KE	1.0	RE155
KE1030	increased 	KE	1.0	RE157
KE1030	increased 	KE	1.0	RE159
KE122	activation glucocorticoid receptor	KE	2.0	RE163
KE494	glucocorticoid receptor agonist activation	KE	-1.5	RE163
KE742	decreased androgen receptor activity	KE	-1.25	RE163
KE785	activation androgen receptor	KE	1.6666666666666667	RE163
KE1030	increased 	KE	1.0	RE163
KE1396	increased glucocorticoid receptor activity	KE	-1.5	RE163
KE1030	increased 	KE	1.0	RE166
KE1194	increase dna damage	KE	1.0	RE166
KE1281	increased dna damage repair	KE	-0.75	RE166
KE1030	increased 	KE	1.0	RE167
KE1030	increased 	KE	1.0	RE175
KE1030	increased 	KE	1.0	RE173
KE1030	increased 	KE	1.0	RE174
KE122	activation glucocorticoid receptor	KE	1.3333333333333333	RE178
KE494	glucocorticoid receptor agonist activation	KE	-1.0	RE178
KE742	decreased androgen receptor activity	KE	-0.75	RE178
KE785	activation androgen receptor	KE	1.0	RE178
KE1396	increased glucocorticoid receptor activity	KE	-1.0	RE178
